X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (18) 18
humans (17) 17
pancreatic cancer (16) 16
chemotherapy (13) 13
medicine & public health (10) 10
adenocarcinoma (9) 9
cancer (8) 8
survival (8) 8
cancer research (7) 7
female (7) 7
gemcitabine (7) 7
male (7) 7
adjuvant chemotherapy (6) 6
care and treatment (6) 6
surgery (6) 6
adenocarcinoma - drug therapy (5) 5
aged (5) 5
middle aged (5) 5
quality of life (5) 5
radiotherapy (5) 5
survival rate (5) 5
adenocarcinoma - pathology (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cisplatin (4) 4
clinical trials (4) 4
diagnosis (4) 4
follow-up studies (4) 4
gastroenterology & hepatology (4) 4
hematology, oncology and palliative medicine (4) 4
metastasis (4) 4
pancreas (4) 4
pancreas cancer (4) 4
pancreatic neoplasms - pathology (4) 4
pancreatic neoplasms - therapy (4) 4
therapy (4) 4
treatment (4) 4
adenocarcinoma - radiotherapy (3) 3
adult (3) 3
cancer chemotherapy (3) 3
cancer patients (3) 3
cancer therapies (3) 3
carcinoma, pancreatic ductal - therapy (3) 3
deoxycytidine - analogs & derivatives (3) 3
double-blind (3) 3
drug administration schedule (3) 3
folfirinox (3) 3
folinic acid (3) 3
health aspects (3) 3
metronomic chemotherapy (3) 3
nab-paclitaxel (3) 3
neoplasm staging (3) 3
pancreatic neoplasms - diagnosis (3) 3
pancreatic neoplasms - drug therapy (3) 3
practice guidelines as topic (3) 3
prognosis (3) 3
prospective studies (3) 3
resection (3) 3
spain (3) 3
treatment outcome (3) 3
adenocarcinoma - mortality (2) 2
adenocarcinoma - surgery (2) 2
adenocarcinoma - therapy (2) 2
adenoviruses (2) 2
american society (2) 2
animals (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
borderline resectable (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
carcinoma (2) 2
carcinoma, pancreatic ductal - diagnosis (2) 2
chemoradiation (2) 2
chemoradiotherapy (2) 2
cisplatin - administration & dosage (2) 2
clinical guides in oncology (2) 2
colorectal-cancer (2) 2
combination (2) 2
combined modality therapy (2) 2
cyclophosphamide (2) 2
càncer de pàncrees (2) 2
deoxycytidine - administration & dosage (2) 2
disease-free survival (2) 2
ductal adenocarcinoma (2) 2
endothelial-cell proliferation (2) 2
esge days 2020 oral presentations (2) 2
esophageal neoplasms - drug therapy (2) 2
esophageal neoplasms - pathology (2) 2
esophageal neoplasms - radiotherapy (2) 2
fluorouracil (2) 2
gemcitabine plus placebo (2) 2
genetics (2) 2
growth-factor (2) 2
health-related quality of life (2) 2
immunotherapy (2) 2
irinotecan (2) 2
management (2) 2
mice (2) 2
mice, nude (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
BMC Cancer, ISSN 1471-2407, 02/2015, Volume 15, Issue 1, pp. 60 - 60
Journal Article
Journal Article
Annals of oncology, ISSN 0923-7534, 2016, Volume 27, pp. vi120 - vi120
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2009, Volume 75, Issue 5, pp. 1430 - 1436
Purpose To determine in a Phase II trial whether preoperative irinotecan–cisplatin (IC) followed by concurrent IC therapy and radiotherapy (IC/RT) improved... 
Radiology | Hematology, Oncology and Palliative Medicine | Irinotecan | Gastric cancer | Cisplatin | Preoperative chemoradiotherapy | SURGERY | SURVIVAL | COMBINED-MODALITY THERAPY | ADVANCED ESOPHAGEAL CANCER | PATHOLOGICAL RESPONSE | CHEMORADIOTHERAPY | CHEMOTHERAPY | ONCOLOGY | CHEMORADIATION | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Adenocarcinoma - pathology | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Stomach Neoplasms - pathology | Esophageal Neoplasms - radiotherapy | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Esophageal Neoplasms - surgery | Camptothecin - administration & dosage | Adenocarcinoma - radiotherapy | Camptothecin - analogs & derivatives | Stomach Neoplasms - radiotherapy | Camptothecin - adverse effects | Drug Administration Schedule | Survival Rate | Stomach Neoplasms - drug therapy | Combined Modality Therapy - adverse effects | Adenocarcinoma - drug therapy | Remission Induction | Spain | Esophagogastric Junction | Algorithms | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Combined Modality Therapy - methods | Stomach Neoplasms - surgery | Esophageal Neoplasms - drug therapy | Adenocarcinoma - surgery | Preoperative Period | Adenocarcinoma | Clinical trials | Radiotherapy | Index Medicus | NEOPLASMS | TOXICITY | ANTINEOPLASTIC DRUGS | MEDICINE | NUCLEAR MEDICINE | DISEASES | THERAPY | DRUGS | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY | COMBINED THERAPY | RADIOLOGY
Journal Article
Journal Article
Clinical and Translational Oncology, ISSN 1699-048X, 12/2016, Volume 18, Issue 12, pp. 1172 - 1178
...CLINICAL GUIDES IN ONCOLOGY SEOM Clinical Guideline for the treatment of pancreatic cancer (2016) R. Vera 1 • E. Dotor 2 • J. Feliu 3 • E. Gonza ´lez 4 • B... 
Oncology | Diagnostic | Treatment | Medicine & Public Health | Pancreatic cancer | Guidelines | ADJUVANT CHEMOTHERAPY | SURVIVAL | FOLFIRINOX | RESECTION | ADENOCARCINOMA | FOLLOW-UP | FOLINIC ACID | FLUOROURACIL | GEMCITABINE | ONCOLOGY | AMERICAN SOCIETY | Pancreatic Neoplasms - diagnosis | Humans | Risk Factors | Treatment Outcome | Pancreatic Neoplasms - therapy | Practice Guidelines as Topic | Spain | Clinical Guides in Oncology
Journal Article
Cirugia Espanola, ISSN 0009-739X, 10/2017, Volume 95, Issue 8, pp. 447 - 456
Introduction: A borderline resectable group (APBR) has recently been defined in adenocarcinoma of the pancreas. The objective of the study is to evaluate the... 
Neoadjuvant | Borderline resectable | Pancreatic surgery | Pancreas cancer
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2011, Volume 67, Issue 1, pp. 75 - 82
Journal Article
Pancreatology, ISSN 1424-3903, 2015, Volume 15, Issue 3, pp. e4 - e5
Journal Article
Annals of oncology, ISSN 0923-7534, 2019, Volume 30, Issue 12, pp. 1959 - 1968
Background: Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase... 
BRCA | pancreatic cancer | FOLFIRINOX | IMPACT | metastatic | ONCOLOGY | olaparib | health-related quality of life | GEMCITABINE | Original
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2013, Volume 133, Issue 10, pp. 2464 - 2472
In this article, the effectiveness of a multi‐targeted chemo‐switch (C‐S) schedule that combines metronomic chemotherapy (MET) after treatment with the maximum... 
metronomic chemotherapy | gemcitabine | chemo‐switch schedule | cancer stem cells | anti‐angiogenic | chemo-switch schedule | anti-angiogenic | SURVIVAL | CYCLOPHOSPHAMIDE | MODEL |